Stanford's Virtual Biotech turns 37,000 AI agents into a drug-discovery factory

Stanford University researchers have developed 'Virtual Biotech,' a multi-agent AI system with 37,000 specialized agents that simulates a full pharmaceutical company, accelerating drug discovery and clinical trial analysis. The system independently designed a lung cancer antibody-drug conjugate later confirmed by Merck and designated breakthrough therapy by the US FDA.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 17 Sep 2026 and 19 Sep 2026.